139.81MMarket Cap-1185P/E (TTM)
2.850High2.290Low11.07MVolume2.580Open1.890Pre Close28.51MTurnover70.96%Turnover RatioLossP/E (Static)52.36MShares4.75052wk High-3.99P/B41.66MFloat Cap1.53052wk Low--Dividend TTM15.60MShs Float19.064Historical High--Div YieldTTM29.63%Amplitude1.530Historical Low2.574Avg Price1Lot Size
Inventiva Stock Forum
MT Newswires· 5 mins ago
Inventiva (IVA.PA) secured new financing primarily earmarked for the phase 3 trial of its lanifibranor treatment for metabolic dysfunction-associated steatohepatitis, a fatty liver disease and its subsequent marketing approval and commercialization.
The clinical-stage biopharmaceutical company secured an immediate financing of 94.1 million euros worth of shares and ...
Benzinga·
The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.
The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in t...
SEC announcement· May 3 21:27
Benzinga· 2 mins ago
Inventiva has lifted the voluntary pause on screening and randomization in the NATiV3 clinical trial following the approval from the US central IRB of the amended protocol and ICF.
Screening of patients is resuming in sites operating under central IRB in the US.
Other sites and countries are expected to resume screening and randomization activities progr...
No comment yet